UCL-led trial shows adding niraparib to standard therapy reduces tumour growth risk in men with advanced prostate cancer by up to 37%, with greater effect in specific genetic subgroups.
Cecilia Van Cauwenberghe from Frost & Sullivan explores advancing opportunities for personalised treatment of chronic kidney disease (CKD) and research into membranous nephropathy (MN)
According...
UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's
Neurodegenerative diseases are...
EUPHA Executive Director, Dineke Zeegers Paget explores the importance of improving public health in Europe
The European Public Health Association – EUPHA – is an...
Experts from the Lymphoma Association offer their thoughts on the extent of lymphoma in the UK today and how treatment and diagnosis can improve
Every...
The European Parkinson’s Disease Association (EPDA) provide an update about the positive progress being made for people with Parkinson’s
My PD Journey is a multi-stakeholder...
Emory University’s Stuart Zola considers the case for classifying Alzheimer’s disease as a spectrum disorder and the promise of precision medicine as an intervention.
Bethany Torr, campaigns and advocacy officer at Leukaemia Care introduces ‘Leukaemia’ and its different forms and explains how people live with the disease
Leukaemia’ is...
